{"id":60044,"date":"2026-03-19T22:33:11","date_gmt":"2026-03-19T14:33:11","guid":{"rendered":"https:\/\/flcube.com\/?p=60044"},"modified":"2026-03-19T22:33:21","modified_gmt":"2026-03-19T14:33:21","slug":"kintor-pharmas-kx-826-hits-phase-iii-endpoint-in-hair-loss-androgen-receptor-antagonist-tincture-shows-15-33-hairs-cm%c2%b2-growth-vs-placebo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60044","title":{"rendered":"Kintor Pharma’s KX-826 Hits Phase III Endpoint in Hair Loss \u2013 Androgen Receptor Antagonist Tincture Shows 15.33 Hairs\/cm\u00b2 Growth vs. Placebo"},"content":{"rendered":"\n

Suzhou Kintor Pharmaceuticals, Inc.<\/strong> (HKG: 9939<\/a>) announced that its pivotal Phase III clinical study<\/strong> for KX-826 tincture 1.0%<\/strong> in hair loss<\/strong> met the primary endpoint<\/strong>, demonstrating statistically significant and clinically meaningful efficacy<\/strong> in Chinese adult male patients with androgenetic alopecia (AGA)<\/strong>. The topical androgen receptor antagonist<\/strong> achieved 15.33 hairs\/cm\u00b2 increase<\/strong> in target area non-vellus hair count (TAHC) vs. 4.68 hairs\/cm\u00b2 for placebo<\/strong>, positioning Kintor to file for China market approval<\/strong> in the near term.<\/p>\n\n\n\n

Phase III Study Results<\/h2>\n\n\n\n
Endpoint<\/th>KX-826 1.0% BID<\/th>KX-826 0.5% BID<\/th>Placebo<\/th>Clinical Significance<\/th><\/tr><\/thead>
TAHC Change (hairs\/cm\u00b2)<\/strong><\/td>+15.33<\/strong><\/td>+14.46<\/strong><\/td>+4.68<\/td>10.65 hairs\/cm\u00b2 advantage<\/strong> (1.0% dose) vs. placebo<\/td><\/tr>
Statistical Significance<\/strong><\/td>p<0.001 (significant)<\/td>p<0.001 (significant)<\/td>\u2014<\/td>Both doses superior<\/td><\/tr>
Safety Profile<\/strong><\/td>Favorable<\/td>Favorable<\/td>\u2014<\/td>No dose-limiting toxicities; topical tolerability confirmed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Study Design:<\/strong> Multicenter, randomized, double-blind, vehicle-controlled Phase II\/III adaptive design; 666 patients<\/strong> in Phase III portion; BID (twice daily)<\/strong> topical application<\/p>\n\n\n\n

Product Profile & Mechanism<\/h2>\n\n\n\n
Attribute<\/th>KX-826 Specification<\/th><\/tr><\/thead>
Mechanism<\/strong><\/td>Androgen receptor (AR) antagonist<\/strong> \u2013 competes with androgens for AR binding in target tissues<\/td><\/tr>
Route<\/strong><\/td>Topical tincture<\/strong> (1.0% and 0.5% formulations)<\/td><\/tr>
Target Pathway<\/strong><\/td>Direct blockade of androgen signaling in hair follicles<\/td><\/tr>
Differentiation<\/strong><\/td>First-in-class topical AR antagonist<\/strong> for AGA; oral finasteride\/dutasteride alternatives have systemic side effect concerns<\/td><\/tr>
Indication<\/strong><\/td>Androgenetic alopecia (male pattern hair loss)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Commercial Outlook<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China AGA Market<\/strong><\/td>~100 million affected males<\/strong>; RMB 20+ billion<\/strong> annual treatment market (pharmaceuticals + procedures)<\/td><\/tr>
Current Standard of Care<\/strong><\/td>Oral finasteride (systemic side effects: sexual dysfunction, mood changes); minoxidil (limited efficacy, requires chronic use)<\/td><\/tr>
KX-826 Positioning<\/strong><\/td>Topical AR blockade<\/strong> offers efficacy with reduced systemic exposure<\/strong>; addresses unmet need for side-effect-averse patients<\/td><\/tr>
Competitive Landscape<\/strong><\/td>Cosmeceuticals dominate; no approved topical AR antagonists; KX-826 first-to-market advantage 2\u20133 years<\/strong><\/td><\/tr>
Revenue Potential<\/strong><\/td>Peak sales RMB 1\u20132 billion annually<\/strong> in China assuming 5\u20138% market penetration; global licensing opportunity $500+ million<\/strong> (U.S., EU AGA markets)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n